Back to top
more

FibroGen (FGEN)

(Delayed Data from NSDQ)

$1.04 USD

1.04
653,315

+0.02 (1.96%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for FGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for FibroGen, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 236 422 405 687 534
Receivables 13 16 17 42 28
Notes Receivable 0 0 0 0 0
Inventories 42 40 31 17 7
Other Current Assets 42 14 20 10 133
Total Current Assets 332 493 474 755 702
Net Property & Equipment 13 21 28 34 43
Investments & Advances 5 9 172 3 61
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 7 8 6 11
Total Assets 424 610 774 827 857
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 18 31 26 25 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 12 12
Accrued Expenses 173 220 173 120 84
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 13 13 16 7 0
Total Current Liabilities 218 274 226 163 103
Mortgages 0 0 0 0 0
Deferred Taxes/Income 158 186 187 138 99
Convertible Debt 0 0 0 0 0
Long-Term Debt 72 0 0 0 0
Non-Current Capital Leases 0 0 0 25 38
Other Non-Current Liabilities 72 73 44 58 81
Minority Interest (Liabilities) 21 0 0 0 0
Total Liabilities 607 612 545 385 322
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,644 1,541 1,476 1,400 1,301
Retained Earnings -1,842 -1,558 -1,264 -974 -785
Other Equity 14 14 16 15 19
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -184 -1 229 441 535
Total Liabilities & Shareholder's Equity 424 610 774 827 857
Total Common Equity -184 -1 229 441 535
Shares Outstanding 98.30 93.90 92.70 91.00 87.20
Book Value Per Share -1.87 -0.02 2.47 4.85 6.14

Fiscal Year End for FibroGen, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 236 251 336 356
Receivables NA 13 32 26 18
Notes Receivable NA 0 0 0 0
Inventories NA 42 41 41 42
Other Current Assets NA 42 40 9 14
Total Current Assets NA 332 364 411 431
Net Property & Equipment NA 13 15 17 19
Investments & Advances NA 5 5 6 6
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 5 6 6 7
Total Assets NA 424 460 515 539
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 18 19 13 71
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 173 171 163 157
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 13 7 7 17
Total Current Liabilities NA 218 209 194 255
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 158 154 165 163
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 72 72 71 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 70 71 73
Minority Interest (Liabilities) NA 21 21 21 0
Total Liabilities NA 607 597 597 567
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,644 1,634 1,625 1,589
Retained Earnings NA -1,842 -1,786 -1,722 -1,634
Other Equity NA 14 14 14 15
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -184 -137 -82 -29
Total Liabilities & Shareholder's Equity NA 424 460 515 539
Total Common Equity 0 -184 -137 -82 -29
Shares Outstanding 98.70 98.30 98.20 97.50 96.70
Book Value Per Share 0.00 -1.87 -1.39 -0.84 -0.30